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Mark A Wainberg1* and Andrew M L Lever2*The dramatic spread of the Ebola virus in countries in
Western Africa over the past year has wreaked havoc
throughout that region and brought panic and fear to mil-
lions of people around the world. There are many similar-
ities between people’s attitudes today toward Ebola virus
and its victims and the attitudes to HIV that were preva-
lent only 25 years ago. In the run-up to World AIDS Day,
December 1, we should reflect on these parallels between
HIV and Ebola virus and what may be the potential impact
of the Ebola crisis on efforts to control the spread of HIV
in the countries that have been so badly affected by both
of these lethal pathogens.
Over 39 million people have already died of HIV disease
and it is estimated that 35 million individuals are currently
infected by the virus. Although the estimated number
of cases of Ebola is still comparatively small – around
17,000 - there is, understandably, widespread fear that
Ebola transmission may intensify. Moreover, a tragically
high proportion of Ebola-infected individuals, possibly
5,000 - 6,000, have died of their disease. Although several
healthcare volunteers from developed countries who
contracted Ebola while working in Western Africa have
died since returning home, other westerners have sur-
vived due, in large part, to the outstanding treatment
that they have received at tertiary care hospitals in their
home countries. As today for HIV, this provides testi-
mony to the far worse prognosis for severe infections in
settings in which appropriate health care is not available.
Again, as for HIV, it underlines the importance of the re-
cent initiatives to set up better health care provision in
Ebola affected countries.
Publicity about Ebola has eclipsed that of HIV, but it is
salutary to remember that approximately 10 times fewer
people die each day in Africa of Ebola than of HIV/AIDS.
However, what is certain is that the Ebola crisis will
have a major effect on HIV/AIDS (and vice versa) in
the countries in which this new epidemic has taken hold.
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article, unless otherwise stated.those infected by Ebola have themselves been health care
professionals, which must have negative consequences for
the care of persons suffering from other diseases including
HIV. Suboptimal treatment and control of HIV in these
areas equates to a population more susceptible to Ebola,
and the understandable shift in attention to Ebola poten-
tially compromises HIV control measures such as HIV
testing, HIV treatment, treatment as prevention, and pre-
vention of mother to child transmission. Furthermore,
accessing HIV clinics in parts of Western Africa may now
be compromised by fear of Ebola and by new constraints
on public transportation. Despite the fact that wealthy
countries contribute billions of dollars annually toward
global HIV drug purchase programmes, the Ebola crisis
has further strained the reservoirs of human resources in
affected areas.
There are parallels in public perceptions of these two
viruses. The panic that Ebola has evoked in Western
Africa - and the West, following repatriation of Ebola-
infected individuals - is reminiscent of attitudes toward
HIV in the 1980s when people of Haitian origin, those in-
dividuals with hemophilia infected through blood prod-
ucts, and the gay population were discriminated against
because they were thought to represent a risk to others
for HIV acquisition.
This same stigma is now attaching to those courage-
ous individuals who have volunteered to provide care to
Ebola-infected individuals in Western Africa, people who
should deserve our deep gratitude. These same attitudes
were prevalent at the start of the AIDS epidemic when the
belief existed that contact with health care professionals
caring for AIDS patients, or with scientists working with
HIV, was a risk for HIV acquisition. Unfortunately,
groundless fears have never prevented unfounded hos-
tile and discriminatory public attitudes.
Today, antiretroviral drugs (ARVs) provide hope to mil-
lions of HIV-infected individuals for a fully productive life
and an extended, perhaps normal, lifespan. This progress
has required many years of basic biomedical, clinical, and
social research that has also resulted in dramatic im-
provements in the potency and tolerability of the ARVs
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paratively little research input. The perceived threat to
Western nations has, as for HIV, triggered new efforts
for Ebola drug discovery and vaccine development, but
research on Ebola is still badly lagging behind. This
situation can only be remedied by providing the neces-
sary financial support and by providing social assistance
for Ebola-infected individuals and their families and
caregivers. Such research, in the case of HIV, not only
improved treatment, but assisted in mitigating the prob-
lems of HIV discrimination and stigmatization as well as
providing an understanding of HIV transmission.
Community engagement will be essential for Ebola, as
was the case for HIV, and implementation of community
awareness sessions and teaching programmes will be
needed if we are to achieve the behavioral and socio-
cultural changes required for elimination of stigmatization
of Ebola-exposed persons. Both the Ebola and HIV epi-
demics highlight the need to strengthen health care sys-
tems in resource-limited settings as well as illustrating
the sorts of measures that will limit Ebola transmission.
Ebola causes an acute disease that often leads to death
rather than a chronic illness; thus, the window for trans-
mission is far less than for HIV, meaning that it should
theoretically be easier to expeditiously end the Ebola epi-
demic compared to HIV. However, the lessons learned
from HIV must be applied to Ebola as quickly as possible.
Hopefully, new research into vaccines and antiviral
drugs, together with public health control measures, will
quickly lead to an end to the Ebola epidemic and restore
normality to the fragile under-resourced societies that
have suffered the most from Ebola. Perhaps the provision
of new health care facilities now being set up in West
Africa will provide support to their infrastructure in the
future, when hopefully Ebola is controlled, and will aid
them in efforts to raise standards of health care generally.
It may even provide new pointers to yet further progress
in the battle against HIV.
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